<strong>Advances in the Molecular Pathogenesis of Parkinson's Disease</strong>

Abstract

ZHANG Na，DOU De-qiang.Advances in the Molecular Pathogenesis of Parkinson's Disease[J]. Acta Neuropharmacologica, 2013, 3(2): 35-42.

[1] Paola Paola. Neurodegenerative movement disorders: the contribution of functional imaging[J]. Curr pin in Neuro, 2004, 17(4):459-466.

[2] Jan Booij, Remco J J Knol. SPECT imaging of the dopaminergic system in (premo-tor) Parkinson’s disease[J]. Parkinsonism Relat Disord, 2007, 13(13):425-428.

[3] Klaus Seppi. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice[J]. Parkinsonism Relat Disord, 2007; 13(pl3):400-405

[4] Rajput A H, Birdi S. Epidemiology of Parkinson's disease[J]. Parkinsonism & Related Disorders, 1997, 3(4):175-186.

[5]Xiromerisiou G, Hadjigeorgiou G M, Gourbali V, et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson’s disease: identification of two novel LRRK2 variants[J]. Eur J Neurol, 2007, 14(1):7–11.

[6] Guo Ji-feng, Zhang Xue-wei, Nie Li-luo, et al. Mutation analysis of Parkin, PINK1 and DJ-1 genesin Chinese patients with sporadic early onset parkinsonism[J]. J Neurol, 2010, 257(7): 1170-1175.

[7] Peter T Lansbury Jr, Alexis Briee. Geneties of parkinson’s disease and bioehemieal studies of imPlieated gene Produets[J]. Curr Opin Genet Dev, 2002, 12(3):299-306.

[8] Rosa M Canet-Aviles, Mark A Wilson, David W Miller, et al. The Parkinson’s disease protein DJ-1 is neruoprotective due to cysteinesulfinic acid-driven mitochondrial localization[J]. Proc Natl Acad Sci USA, 2004, 101(24):9103-9108.

[9]Ross O A, Soto A I, Vilarino-Guell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease [J]. Disord, 2008, 14(7):539–543.

[10] Carola Schiesling，Nicole Kieper，Kay Seidel，et al．Review: familial Parkinson’s disease genetics，clinical phenotype and neuropathology in relation to the common sporadic form of the disease[J]. Neuropathol Appl Neurobiol, 2008, 34(3):255-271．

[11] Shinji Higashi, Darren J Moore, Rebecca E Colebrooke. et al. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain[J]. J Neurochem, 2007, 100(2):368–381.

[12] Serge Przedborski, Harry Ischiropoulos. Reactive oxygen and nitrogen species: weapons ofneuronal destruction in models of Parkinson's disease[J]. Antioxid Redox Signal, 2005, 7(5-6):685-693.

[13] David C Dorman, Anna M Mcelveen, Marianne W Marshall, et al. Tissue manganese concentrations inlactating rats and their offspring following combined in utero and lactation exposure to inhaledmanganese sulfate[J]. Toxicol Sci, 2005, 84(1):12-21.

[14] Keiko Imamura, Takao Takeshima, Yoshihiro Kashiwaya, et al. D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease[J]. J Neurosci Res, 2006, 84(6):1376-1384.

[15] Hiroshi Kawai, Yukiko Makino, Masaaki Hirobe, et al. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism[J]. J Neurochem, 1998, 70(2):745-751.

[16] Ravindar R Thomas, Paula M Keeney, James P Bennett. Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex[J]. J Parkinsons Dis, 2012, 2(1):67-76.

[17] Laurie H Sanders, J Timothy Greenamyre. Oxidative damage to macromolecules in human Parkinson disease and the rotenone model[J]. Free Radic Biol Med, 2013, 62: 111-120.

[18] 黄桂平. 帕金森病的临床研究及展望[J]. 医学综述，2008，14（13）：2023-2026.

[19] Gail D Zeevalk, Laura P Bernard, William J Nicklas. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism[J]. J Neurochem, 1998, 70(4): 1421-1430.

[20] Vernica Jackson-Lewis, Michael Jakowec, Robert E Burke, et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine [J]. Neurodegeneration, 1995, 4(3): 257-269.

[21] 项喜艳. DTT诱发内质网应激-自噬过程中活性氧的作用及其调节机制[D].中国优秀博硕士学位论文全文数据库（硕士）：吉林大学，2012.

[22] 王虎，蔡定芳.帕金森病与内质网应激[J]. 国际神经病学神经外科学杂志，2007，34（1）：86-90

[23] 邓娟，白洁. TRPC1和Ca2+在帕金森病内质网应激中的作用[J]. 生命科学，2012，24（10）：1169-1173.

[24] Gail D Zeevalk, Laura P Bernard. Energy status, ubiquitin proteasomal function, and oxidative stress during chronic and acute complex I inhibition with rotenone in mesencephalic cultures [J]. Antioxid Redox Signal, 2005, 7(5-6): 662-672.

[25] Liu Ming-chao, Cai Tong-jian, Zhao Fang, et al. Effect of microglia activation on dopaminergic neuronal injury induced by manganese, and its possible mechanism[J]. Neurotox Res, 2009, 16(1): 42-49.

[26] Verkhratsky A, Toescu E C. Neuronal-glial networks as substrate for CNS integration [J]. J Cell Mol Med, 2006, 10(4):826-836.

[27] Mahmoud M Iravani, Clement C Leung, Mona Sadeghian, et al. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation[J]. Eur J Neurosci, 2005, 22(2): 317-330.

[28] Toshi Nagatsu, Makoto Sawada. Cellular and molecular mechanisms of Parkinson's disease:neurotoxins, causative genes, and inflammatory cytokines[J]. Cell Mol Neurobiol, 2006, 26(4-6): 781-802.

[29] W Michael Caudle, Zhang Jing. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease[J]. Exp Neurol, 2009, 220(2): 230-233.

[30] Patrica A Trimmer, Trisha S Smith, Anthony B Jung, et al. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity[J]. Neurodegeneration, 1996, 5(3):233-239.

[31] Oren A Levy, Cristina Malagelada, Lloyd A Greene. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps[J]. Apoptosis, 2009, 14(4): 478-500.

[32] Karl Kieburtz, Bernard Ravina. Why hasn't neuroprotection worked in Parkinson's disease[J]. Nat Clin Pract Neurol, 2007, 3(5): 240-241.

[33] Jorg B Schulz. Mechanisms of neurodegeneration in idiopathic Parkinson's disease[J]. Parkinsonism Relat Disord, 2007, 13 (Suppl 3): S306-S308.

[34] Kaivalya J Vyas, John H Weiss. BMAA--an unusual cyanobacterial neurotoxin[J]. Amyotroph Lateral Scler, 2009, 10 (Suppl 2): 50-55.

Advances in the Molecular Pathogenesis of Parkinson's Disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

[1]	王奇.Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease[J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.
[2]	ZHONG Jia-hong, WANG Hai-tao, XU Jiang-ping.Inhibition of Phosphodiesterase 4 by FCPR16 Protects SH-SY5Y Cells against MPP+-Induced Cell Death through Activating cAMP/PKA/CREB and Epac/Akt Signaling Pathways[J]. Acta Neuropharmacologica, 2018, 8(4): 54-55.
[3]	GAO Zhi-hong1，ZUO Ya-qi2，ZHANG Xiao-li1.A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(5): 39-44.
[4]	WAN Ye，GUO Chun-yan，LI Yong-min.Research Progress of Traditional Chinese Medicine in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(4): 36-42.
[5]	ZHANG Li-na，ZHANG Xin，XUE Juan，ZHANG Dan-shen.Advances Achievements of Traditional Chinese Medicine on the Signaling Pathways in Central Nervous Degenerative Diseases[J]. Acta Neuropharmacologica, 2017, 7(3): 33-42.
[6]	WANG Lin-fang，HUANG Shu-bing，XU Yi-da，CUI Chun，SHEN Yan-qin.Effects of Loganin on MPTP-Induced Autophagy in PC12 Cells[J]. Acta Neuropharmacologica, 2016, 6(5): 14-21.
[7]	ZHANG Mei-jin，WANG Sha-sha，ZHANG Zhao，CHEN Nai-hong，HU Jin-feng.Role of Nuclear Transcription Factor Nrf2 in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2016, 6(1): 35-40.
[8]	LOU Yu-xia，ZHANG Zhao，WANG Zhen-zhen，JIANG Yi-na，ZHANG Yi，LI Lin，CHEN Nai-hong.Parkinson Associated DJ-1 Gene and Oxidative Stress[J]. Acta Neuropharmacologica, 2016, 6(1): 58-64.
[9]	GAO Yang，DUAN Leng-xin.Advances of Autophagy in Parkinson’s Disease and Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2015, 5(3): 22-27.
[10]	HAO Jun-rong，SHEN Li-xia.The Research Progress of Proteomics Used in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2015, 5(3): 28-35.
[11]	JIANG Yi-na, CHEN Nai-hong.Advances in Parkinson’s Disease-Causing Gene Parkin[J]. Acta Neuropharmacologica, 2015, 5(3): 36-45.
[12]	WU Zhi-gang，SHEN Li-xia.Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease[J]. Acta Neuropharmacologica, 2014, 4(4): 36-41.
[13]	Zhang Zhao, Chu Shi-feng, Huang Hui-yong, Chen Nai-hong.Long Noncoding RNAs：Research Strategies and Progresses in Neurodegenerative Diseases[J]. Acta Neuropharmacologica, 2014, 4(4): 42-49.
[14]	WANG Jin.Non-motor Symptoms of Parkinson’s Disease[J]. Acta Neuropharmacologica, 2013, 3(6): 44-47.
[15]	WANG Qi，DUAN Leng-xin.Progress on the Involvement of GRP78 and ATF4 – CHOP – Puma Signaling Pathway in Endoplasmic Reticulum Stress and Parkinson's Disease[J]. Acta Neuropharmacologica, 2013, 3(3): 19-26.